A5031146373- Health Systems, Economic Evaluations, Quality of Life
- Urinary Bladder and Prostate Research
- Pelvic floor disorders treatments
- Pharmaceutical Practices and Patient Outcomes
- Medication Adherence and Compliance
- Diabetes Treatment and Management
- Schizophrenia research and treatment
- Bladder and Urothelial Cancer Treatments
- Urinary Tract Infections Management
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Blood Pressure and Hypertension Studies
- Economic and Financial Impacts of Cancer
- Chronic Disease Management Strategies
- Opioid Use Disorder Treatment
- Obesity, Physical Activity, Diet
- Dementia and Cognitive Impairment Research
- Protease and Inhibitor Mechanisms
- Diabetes Management and Research
- Obesity and Health Practices
- Pharmaceutical studies and practices
- Pharmaceutical industry and healthcare
- Cardiovascular Syncope and Autonomic Disorders
- Pharmacology and Obesity Treatment
- Diabetes Management and Education
Humana (United States)
2016-2025
University of Kentucky HealthCare
2019-2022
Comprehensive Clinical Research
2015-2018
The University of Texas at Austin
2005-2011
Austin College
2009
Alzheimer's disease (AD) represents a serious public health issue affecting approximately 5.4 million individuals in the United States and is projected to affect up 16 by 2050. This study examined care resource utilization (HCRU), costs, comorbidity burden immediately preceding new diagnosis of AD 2 years after diagnosis.
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that can lead to visual impairment. Published studies estimate approximately 1 million people in the United States have GA at least eye. There a lack real-world evidence from US payer perspective on prevalence AMD and among Medicare Advantage prescription drug (MAPD) plan enrollees.
Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and responsible for approximately 20% legal blindness in the United States. There limited real-world evidence assessing health outcomes care resource use (HCRU) among individuals with GA.
Background: Alpha-1 antitrypsin deficiency (AATD) testing rates and associated clinical economic outcomes data in the US Medicare population are limited. Objective: To characterize individuals with AATD, describe outcomes/healthcare research utilization (HCRU) among chronic obstructive pulmonary disease (COPD) or without identify AATD newly diagnosed COPD. Methods: This retrospective, observational analysis of claims included from Humana Research Database (aged 18-89 years) enrolled...
Readmission is costly among patients with type 2 diabetes (T2DM) in Medicare Advantage Prescription Drug Plans; identifying high-risk necessary for targeting reduction programs. The objective of this study was to develop a claims-based algorithm predict all-cause 30 day readmission T2DM.This used administrative data from 1 January 2012 through 31 2014. cohort included hospitalized T2DM patients, aged 18-90 ≥12 months' continuous enrollment before an unplanned hospital admission and ≥1 month...
Objectives To compare medical condition burden, healthcare resource use, and costs of household members ( HHM s) individuals diagnosed with A lzheimer's disease AD ) those s matched without . Design Retrospective cohort study based on administrative claims data collected between J anuary 1, 2007, D ecember 31, 2011. Setting M edicare dvantage P rescription rug MAPD plan. Participants plan a diagnosis International C lassification Disease N inth R evision, linical Modification , code 331.0)...
To examine the association of obesity with healthcare resource utilization and costs in a Medicare population.This study was retrospective cohort using Humana Advantage (MA) claims data. Body mass index (BMI) assessed ICD-9-CM status codes (V85 hierarchy) that have been validated data source to classify patients into BMI categories: normal (N), overweight (Ow), obese class I (ObI), II (ObII), III (ObIII). Healthcare (HRU) were determined based on Descriptive statistics used baseline...
Objectives To examine potentially inappropriate medication ( PIM ) use in older adults initiating an antimuscarinic for the treatment of overactive bladder OAB ). Design Retrospective database analysis. Setting Medical and pharmacy claims data. Participants Medicare Advantage Prescription Drug Plan members aged 65 newly initiated on were identified assigned to non‐ comparison groups based 2012 American Geriatrics Society Beers Criteria and/or presence anticholinergic interaction at time...
To examine the association of obesity with healthcare resource utilization (HRU) and costs among commercially insured individuals.This retrospective observational cohort study used administrative claims from 1 January 2007 to December 2013. The ICD-9-CM status codes (V85 hierarchy) 2008 2012 classified body mass index (BMI) into World Health Organizations' BMI categories. date first observed code was defined as continuous eligibility for one year pre- post- ensured. Post-index determined...
Background The study examined the prevalence of early treatment revisions after glycosylated hemoglobin (HbA1c) ≥9.0% (75 mmol/mol) and estimated impact on glycemic control, diabetic complications, costs. Research design methods A retrospective cohort administrative claims data plan members with type 2 diabetes HbA1c was completed. Treatment revision identified as addition or switch. Glycemic control measured during 6–12 months following first qualifying laboratory result. Complications...
Abstract Background Use of anticholinergic (ACH) medications is associated with increased risk cognitive decline in the elderly. However, little known about this association from a health plan perspective. Methods This retrospective cohort study used Humana Research Database to identify individuals at least one ACH medication dispensed 2015. Patients were followed until incidence dementia/Alzheimer’s disease, death, disenrollment or end December 2019. Multivariate Cox regression models...
Abstract Background Managed healthcare organizations often utilize formulary management strategies such as prior authorization and step therapy to guide appropriate medication use control expenditures. The objective of this study was examine clinical economic outcomes associated with implementation a pregabalin ( ST ) policy among Medicare Advantage Prescription Drug MAPD members. Methods Pharmacy medical claims data from Humana (restricted cohort; implemented 01/01/2009) Thomson Reuters...
Varenicline, a nicotinic acetylcholine receptor partial agonist, is pharmacotherapy indicated for smoking cessation treatment. To date, no research has examined the relationship between out-of-pocket (OOP) expense and varenicline adherence among Medicare beneficiaries.To (a) characterize medication utilization patterns of members newly initiated on (b) examine member OOP adherence.In this retrospective cohort study, pharmacy claims data were used to identify Advantage Prescription Drug Plan...
BACKGROUND: More than 30% of Medicare beneficiaries and 40% patients dually eligible for Medicaid use opioids. With an estimated 8%-12% developing opioid disorder (OUD) after initiating opioids, misuse is a significant public health challenge, especially among high-risk populations. Medication-assisted treatment (MAT) the medications OUD to prevent relapse use. MAT most effective OUD. There are variety barriers therapy that may delay access treatment. OBJECTIVE: To study impact removal prior...
During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased vital signs vs placebo in patients overactive bladder.The purpose of this study to compare incidence rates adverse cardiovascular (CV) outcomes following mirabegron or antimuscarinic use.We conducted an observational post-marketing safety utilising real-world data. The population identified within five sources: Danish and Swedish National Registers, Clinical Practice Research Datalink (UK), Optum...
To compare changes in healthcare resource utilization and costs among members with painful diabetic peripheral neuropathy (pDPN), postherpetic neuralgia (PHN), or fibromyalgia (FM) a commercial health plan implementing pregabalin step-therapy unrestricted plans.Retrospective study of outcomes associated implementation protocol using claims data from Humana ('restricted' cohort) Thomson Reuters MarketScan ('unrestricted' cohort). Members aged 18-65 years receiving treatment for pDPN, PHN, FM...
Anticipating and controlling drug-drug interactions (DDIs) in older patients with painful diabetic peripheral neuropaty (pDPN) presents a significant challenge to providers. The purpose of this study was examine the impact newly initiated pregabalin or duloxetine treatment on Medicare Advantage Prescription Drug (MAPD) plan pDPN patients' encounters potential interactions, healthcare cost utilization consequences those opioid utilization.Study subjects required pharmacy claim between...
Aim: To compare adherence, healthcare utilization and costs among real world, Medicare-eligible patients with schizophrenia using long-acting injectable paliperidone palmitate (PP) versus oral atypical antipsychotics. Patients & methods: Historical cohort study used Medicare Advantage claims data. Inverse probability of treatment weighting was applied to adjust for baseline differences. 12-month were compared. Results: PP more adherent (proportion days covered ≥0.8; 48.1 vs 32.6%; p <...
The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron fesoterodine, were removed from Humana Medicare Advantage Prescription Drug (MAPD) plans prescription drug (PDP), allowing an examination the effect ST medication use patterns costs.